drugset / Trial / NCT05417386
FOLFIRINOX + NIS793 in Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This research is being done to evaluate the safety and effectiveness of the drug NIS793 in combination with the standard of care treatment FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin), chemoradiation and surgery for people with metastatic pancreas adenocarcinoma. The drugs involved in this study are: * NIS793 * FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and Leucovorin) Other interventions include * chemoradiation * surgery.
Timeline
- Start
- 2022-08-09
- Primary completion
- 2023-07-10
- Completion
- 2023-07-10
Outcome
Outcome not reported
Stopped: “NIS793 is no longer being developed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NISEVOKITUG | Monoclonal antibody | — | Intravenous |
| Background | Capecitabine | Small molecule | — | Oral |
| Background | Irinotecan | Small molecule | — | Intravenous |
| Background | Leucovorin | Small molecule | — | Intravenous |
| Background | Oxaliplatin | Small molecule | — | Intravenous |
| Background | fluorouracil | Small molecule | — | Intravenous |